Affinivax is a biotechnology company that is developing a new type of vaccine technology. The company's platform is based on a protein that is found on the surface of bacteria. This protein is used to create a vaccine that can provide broad protection against multiple strains of bacteria. Affinivax's technology has the potential to address the growing problem of antibiotic resistance. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.